Publication of 20-Year Outcomes of Oncotype DX GPS Test

Returning guest, Dr. Eric Klein, Chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic discusses new 20-year outcomes from a development study of the Oncotype DX Genomic Prostate Score® (GPS) test that was recently published in JCO Precision Oncology (March 2021).  The study highlights the role of the GPS test, the only genomic test for prostate cancer with 20-year outcomes, in assessing the risk of long-term distant metastases (DM) and prostate cancer-specific mortality (PCSM) for patients with localized prostate cancer. 

Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate, testis, and kidney. For several years, including the current edition, Dr. Klein is listed in Best Doctors in America.

Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He was the National Medical Study Coordinator for the National Cancer Institute-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic.

Dr. Klein received his medical degree from the University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.